In a report released yesterday, Trung Huynh from RBC Capital maintained a Hold rating on GlaxoSmithKline, with a price target of p1,975.00. Huynh covers the Healthcare sector, focusing on stocks such ...

Berenberg Bank analyst Kerry Holford reiterated a Hold rating on GlaxoSmithKline today and set a price target of p2,200.00. According to TipRanks, Holford is a 4-star analyst with an average return of ...

Berenberg analyst Kerry Holford upgraded GlaxoSmithKline (GSK:LN) (NYSE: GSK) from Hold to Buy with a price target of GBP22.00 (from GBP20.00).The analyst comments: Following the spin-off ...

Key Points Interested in GSK PLC Sponsored ADR? Here are five stocks we like better. GSK is expanding oncology across lung, ...

Berenberg analyst Kerry Holford upgraded GlaxoSmithKline (NYSE: GSK) from Hold to Buy with a price target of $60.00 (from $54.00). For an analyst ratings summary and ratings ...

Prime Minister Kretschmer spoke out clearly in the state parliament regarding the pharmaceutical company GSK's plans to close ...

GSK will acquire a trispecific T cell engager for multiple myeloma from Chimagen Biosciences in a deal worth up to $750 ...

GSK trades at GBX1,860.50 today, up 0.4%. Key technicals highlight sideways movement and volatility in the short term.

Shareholders approved appointment of Karine Natland as non-executive director with 99.71% vote share. Bhushan Akshikar re-appointed as managing director with 99.71% shareholder approval. Promoter ...

GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

GSK (LSE:GSK) agreed to acquire Chimagen's trispecific T cell-engager candidate for multiple myeloma, expanding its blood cancer research portfolio. The drug asset is described by the parties as a ...